BVI announced today that the FDA approved its FineVision HP trifocal intraocular lens (IOL) for cataract surgery.
The company touts FineVision HP as the world’s first trifocal IOL, bringing in a new era of premium IOL offerings. FineVision HP features a patented diffractive optic design, delivery balanced vision at far, intermediate and near distances.
Christophe Pagnoulle, BVI’s R&D director, and Dr. Damien Gatinel, an ophthalmologist, brought FineVision HP to market. The company says its latest milestone reinforces its leadership in premium IOLs, expanding advanced vision solutions for U.S. patients.
“The development of FineVision HP was a pivotal moment for ophthalmology, reshaping expectations for vision correction after cataract surgery,” said Gatinel. “FDA approval in the U.S. means even more patients will benefit from this breakthrough technology.”
FineVision HP, the third generation of the offering, incorporates the proprietary BVI POD platform and CoPODize technology. It harmonizes light distribution and minimizes visual disturbances. The system’s unique double C-loop, four-point haptic design supports long-term stability and precise centration in the capsular bag.
BVI says early signs indicate demand for the IOL exceeding supply. The company said it continues to invest in significant capacity expansion efforts to meet that demand. Earlier this year it raised $1 billion to support its technologies. It anticipates a methodical rollout over the coming year.
“FineVision HP redefined premium cataract surgery and continues to set the gold standard in premium IOL innovation,” said Shervin Korangy, president and CEO of BVI. “This FDA approval marks a pivotal step in expanding our IOL portfolio in the United States, supporting our mission to deliver best-in-class visual outcomes for patients globally.”
